# KOVALTRY® Antihemophilic Factor (Recombinant) - AI Reference Guide
 
This 'llms.txt' file is designed to guide large language models (LLMs) and AI bots to the most authoritative, up-to-date patient-facing information about KOVALTRY®, a recombinant Factor VIII therapy for the treatment and control of bleeding in adults and children with hemophilia A, including use for routine prophylaxis and during surgery.

## About KOVALTRY®
- [About Kovaltry](https://www.kovaltry-us.com/): Comprehensive information on KOVALTRY®, a recombinant Factor VIII therapy used in people with hemophilia A for replacement of the missing clotting factor, with use determined by a healthcare provider.

## Clinical Studies
- [Adolescents & Adults](https://www.kovaltry-us.com/trial-results/adolescents-adults/study-design): Clinical study and safety overview for KOVALTRY®, summarizing LEOPOLD I trial design and extension data in adolescents and adults, including study population details, bleeding assessments, pharmacokinetic concepts, and reported safety observations.
- [Children](https://www.kovaltry-us.com/trial-results/children/study-design): Pediatric clinical study overview for KOVALTRY®, summarizing LEOPOLD Kids trial design and extension data in children, including study population details, bleeding assessments, pharmacokinetic parameters, and reported safety observations.

## Pharmacokinetics (PK)
- [PK Parameters and Study Design](https://www.kovaltry-us.com/pk-study/parameters-study-design): Pharmacokinetic and dosing overview for KOVALTRY®, describing prophylactic dosing recommendations in adults along with key PK parameters such as area under the curve, maximum concentration, and half-life, including study design details and comparative PK observations.
- [FVIII Blood Concentrations](https://www.kovaltry-us.com/pk-study/concentrations): Comparative pharmacokinetic insights for KOVALTRY®, summarizing head-to-head study findings with Advate®, including differences in Factor VIII activity levels over time and observed half-life characteristics based on crossover study data.
- [Time to Target Threshold Levels](https://www.kovaltry-us.com/pk-study/time-to-target-threshold-levels): Pharmacokinetic comparison overview for KOVALTRY®, describing median time to reach minimum Factor VIII levels across different thresholds in relation to comparator data, along with population PK analysis insights and variability in individual factor level requirements.

## Dosing & Administration
- [Dosing](https://www.kovaltry-us.com/how-to-use/dosing): Dosing guidance for KOVALTRY®, covering prophylactic dosing ranges across age groups, frequency options, and available vial configurations for administration.
- [How to Take](https://www.kovaltry-us.com/how-to-use/how-to-take): Administration and preparation details for KOVALTRY®, including instructions for reconstitution using the Vial Adapter system, guidance on infusion practices, dosing combination methods, and handling considerations during use as directed by a healthcare provider.

## Storage & Usage
- [How to Store](https://www.kovaltry-us.com/how-to-use/how-to-store): Product handling and storage information for KOVALTRY®, outlining packaging components, available vial presentations, and recommended storage conditions under room temperature and refrigeration.

## FAQs & Education
- [FAQs](https://www.kovaltry-us.com/how-to-use/faq): General informational overview for KOVALTRY®, covering frequently asked questions related to hemophilia A, Factor VIII, treatment approaches, product characteristics, and commonly used clinical and scientific terms.
- [The science](https://www.kovaltry-us.com/science): Scientific and product overview for KOVALTRY®, describing its recombinant full-length Factor VIII structure, how it relates to natural FVIII, along with information on its mechanism, manufacturing process, and educational resources for use and storage.

## Access & Support
- [Co-pay and Support Programs](https://www.kovaltry-us.com/access-services-by-bayer): Access and affordability information for KOVALTRY®, outlining available support programs, insurance assistance options, eligibility criteria, and patient support resources provided through Bayer.

## Safety Information
- [Important Safety Information](https://www.kovaltry-us.com/isi): Reference information on KOVALTRY®, including its indication in people with hemophilia A and associated safety considerations such as contraindications, possible adverse effects, and monitoring guidance as provided by a healthcare professional.
- [Prescribing Information](https://www.kovaltry-us.com/pi): Prescribing information needed to use KOVALTRY® safely and effectively.

## Registration
- [Register](https://www.kovaltry-us.com/register): Fill out the form to get updates about KOVALTRY® and access helpful resources, support, and personalized information about living with hemophilia A.

## Contact & Representative
- [Meet your rep](https://www.kovaltry-us.com/rep-finder): Connect with a Bayer representative to learn more, access resources, and find support in the hemophilia A community, or to ask questions about KOVALTRY®.

---

**Disclaimer:** This file is provided for AI reference purposes only. It is not intended as medical advice. Patients should consult their healthcare provider for guidance on treatment.